<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80744">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078947</url>
  </required_header>
  <id_info>
    <org_study_id>EU 602405-2</org_study_id>
    <nct_id>NCT02078947</nct_id>
  </id_info>
  <brief_title>Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure</brief_title>
  <acronym>OptimEx-Clin</acronym>
  <official_title>Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure- Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <authority>Germany: Ethics Commisson</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the clinical multicenter study (OptimEx-CLIN) is to assess the optimal exercise
      intervention in patients with Heart Failure with preserved Ejection Fraction (HFpEF; also
      termed diastolic heart failure) that will best improve peak oxygen uptake (Peak Vo2) and
      additionally diastolic function (assessed echocardiographically). The investigators
      hypothesize that exercise training reverses HFpEF and that intensity of exercise training is
      more important than duration.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Peak VO2 after three months</measure>
    <time_frame>Baseline and three months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Peak VO2 after three month intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in E/e' (representing diastolic filling pressure) at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in E/e' at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Peak VO2 at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NTproBNP at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NTproBNP at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in HRQOL as measured by the Kansas City Cardiomyopathy Questionnaire at baseline and three months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related Quality of life at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in HRQOL as measured by the Kansas City Cardiomyopathy Questionnaire at baseline and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Atrial Volume Index (LAVI) at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Left Atrial Volume Index (LAVI) at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in e' medial at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in e' at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in submaximal exercise capacity at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
    <description>submaximal exercise capacity will be measured using watts at the first ventilatory threshold (VT1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in submaximal exercise capacity at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Submaximal exercise capacity will be measured using watts at the first ventilatory threshold (VT1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VE/VCO2 slope at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VE/VCO2 slope at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Flow Mediated Dilation (FMD) at baseline and three months</measure>
    <time_frame>three months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Flow Mediated Dialation (FMD) at baseline and 12 months</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>High Intensity Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients perform interval- type endurance exercise at high intensity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Continuous Exercise</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients perform endurance exercise at moderate intensity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients receive advice on being physically active as well as usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>High Intensity Exercise</intervention_name>
    <arm_group_label>High Intensity Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Moderate Continuous Exercise</intervention_name>
    <arm_group_label>Moderate Continuous Exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sedentary (structured exercise &lt; 2x 30 min/wk)

          -  At least 40 years old

          -  Preserved systolic function LVEF &gt; 50%

          -  Signs and symptoms of heart failure class NYHA II or III

          -  Diastolic dysfunction (E/é &gt; 15 or E/é 8-15 and NT-proBNP &gt; 220 pg/ml)

          -  Clinically stable for &gt;= 6 weeks

          -  Optimal medical treatment for &gt;= 6 weeks

          -  Written informed consent

        Exclusion Criteria:

          -  Non- HFpEF causes for HF symptoms (significant valvular or coronary disease,
             uncontrolled hypertension or arrhythmias, primary cardiomyopathies)

          -  Significant pulmonary disease (FEV1 &lt; 50% predicted, COPD GOLD III-IV)

          -  Inability to exercise or conditions that may interfere with exercise intervention

          -  Myocardial infarction in the previous three months

          -  Signs of ischemia during exercise testing

          -  Comorbidity that may influence one- year prognosis

          -  Participation in another clinical trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Halle, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Technische Universität München, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Halle, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technische Universität München, Munich, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Burkert Pieske, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Graz, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christiaan Vrints, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antwerp University Hospital, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volker Adams, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Leipzig, Leipzig, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrik Wisløff, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian University of Science and Technology, Trondheim, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Axel Linke, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heart Center Leipzig, Leipzig, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christiane Heinrich, M.D.</last_name>
    <phone>+498928924446</phone>
    <email>heinrich@sport.med.tum.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Heart Center, Medical University Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin/ Kardiologie, Herzzentrum Leipzig- Universitätsklinik</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Prevention, Rehabilitation and Sports Medicine, Technische Universität München</name>
      <address>
        <city>Munich</city>
        <zip>80992</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Circulation and Medical Imaging, Norwegian University of Science and Technology</name>
      <address>
        <city>Trondheim</city>
        <zip>7491</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.ntnu.edu/optimex</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>February 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diastolic heart failure, Heart failure with preserved ejection fraction, exercise</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
